fda semaglutide shortage resolved 2025 announcement Announces What Patients Need to Know

View our FDA listing

The medication's success underscores the value of targeting incretin pathways in treating metabolic disorders and highlights the chronic nature of conditions like obesity that benefit from ongoing management rather than short-term interventions

Learn about generic semaglutide in Canada: expected release dates, regulatory updates, and cost differences

Ozempic Butt describes loss of subcutaneous fat in the buttocks region during GLP-1 receptor agonist therapy

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand

Key Takeaways Retatrutide acts as a GLP-1 drug to promote weight loss and curb appetite